TAG:
commercial laboratory
Innovative Approach Promises Integration of Clinical Lab Data
By Robert Michel | From the Volume IV No. 12 – August 25, 1997 Issue
CEO SUMMARY: Any laboratory executive with several years in the business has confronted the limitations of laboratory information system (LIS) software. For a variety of reasons, LIS software seldom delivers the full range of benefits and cost-effectiveness sought by laboratories. But in …
Quest Diagnostics, Sonora Join Phoenix Operations
By Robert Michel | From the Volume IV No. 11 – August 4, 1997 Issue
CEO SUMMARY: When Quest Diagnostics Incorporated and Sonora Laboratory Sciences announced their joint venture, it confirmed that Quest Diagnostics is the first of the national laboratories to begin serious restructuring of its national network of regional laboratories. Such restructuring …
Joint Venture In Phoenix To Be Copied Elsewhere
By Robert Michel | From the Volume IV No. 11 – August 4, 1997 Issue
CEO SUMMARY: Look for the Quest-Sonora joint venture to be followed by others in coming months. Competition and marketplace realities are forcing the three national laboratories to respond with groundbreaking strategies. Hospital laboratory partners in these deals can reap significant ben…
Where Are “Laboratories Of The Future?”
By R. Lewis Dark | From the Volume IV No. 9 – June 23, 1997 Issue
At this year’s Executive War College in New Orleans last May 20-21, there was plenty of talk about the radical changes laboratories are undergoing. But one question went unanswered: If laboratories must change, what should they look like after they change? Our Editor, Robert Michel, criss-crosses …
Market Assessment Leads Quest To Do Several Deals
By Robert Michel | From the Volume IV No. 9 – June 23, 1997 Issue
CEO SUMMARY: Quest CEO Ken Freeman is moving rapidly to restructure Quest’s regional laboratory system. Using the financial head-start provided by the January spin-off from Corning, Inc., Quest purchased one laboratory and seeks to do joint venture deals in several cities. Quest’s act…
Pap Smear Technologies Battle For Market Share
By Robert Michel | From the Volume IV No. 9 – June 23, 1997 Issue
CEO SUMMARY: Cytyc, NeoPath and Neuromedical each tapped the public capital markets during the past 18 months. Now investors expect to see earnings growth and dividends as soon as possible. Clinical laboratories should expect intensified sales and marketing efforts from these three compan…
National Labs Cut Costs Using Radical Strategies
By Robert Michel | From the Volume IV No. 8 – June 2, 1997 Issue
CEO SUMMARY: All three national laboratories are dumping unprofitable accounts and unprofitable lines of testing. It ends the era when commercial labs “gave away” testing to any client willing to open an account. The three national laboratories are enacting stiffer requirements for ne…
National Lab Strategies Will Impact Competitors
By Robert Michel | From the Volume IV No. 8 – June 2, 1997 Issue
CEO SUMMARY: Not since the era of commercial lab consolidation ended has such a significant trend emerged. As the three national labs eliminate service to unprofitable accounts, profound changes will occur to the market for laboratory and pathology services. How quickly this leads to impr…
Smythe Teaches Methods To Lift Operating Profits
By Robert Michel | From the Volume IV No. 8 – June 2, 1997 Issue
CEO SUMMARY: Efforts by national laboratories to improve profit margins will affect all laboratories. Consequences of this initiative will actually benefit competitors. It provides all laboratories with the opportunity to increase profits. Mark Smythe demonstrates how this can be accompli…
Roche Holdings, Ltd. Acquires Boehringer Mannheim In Merger
By Robert Michel | From the Volume IV No. 8 – June 2, 1997 Issue
CEO SUMMARY: Roche will pay $11 billion to buy Corange Ltd., parent company of Boehringer Mannheim, the world’s number two diagnostics company. Wall Street expects this deal to quicken the pace of consolidation in the healthcare industry. The surprise move will impact clinical laborator…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized